257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business

Eli Lilly’s investigational medicine for Alzheimer’s met its goals in an all-important clinical trial, and we explain the results, their implications, and the backstory of what could be a blockbuster drug. We also discuss the latest news in the life sciences, including a busy week of earnings, a long-awaited FDA approval, and the highlights from STAT’s Breakthrough Summit in San Francisco.

Episode metadata supplied by the publisher feed · Published May 4, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business

0:00 34:58

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Readout Loud?

This episode is 34 minutes long.

When was this The Readout Loud episode published?

This episode was published on May 4, 2023.

Can I download this The Readout Loud episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!